RxDoctor Payments Data

David Antecol, MD

Cardiovascular Disease · Watertown, NYNPI 1992783344

Payments from drug & device makers

$19,540in general payments, 2019–2025

Across 84 payments — averaging $232.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$15K
  • Medtronic$3K
  • Abbott$396
  • Biotronik Inc.$277
  • Edwards Lifesciences$199
  • Boston Scientific$153
  • plus $517 from 10 others

What the payments were for

  • Consulting fees$2,60013%
  • Speaking & faculty fees$13,88871%
  • Travel & lodging$1,0075%
  • Food & beverage$2,00110%
  • Education$440%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,540 in reported general payments places this provider in the 85th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$67,465
Medicare patients
924
Services billed
1,854

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban287$317,588
EntrestoSacubitril/Valsartan224$209,517
JardianceEmpagliflozin163$161,951
FarxigaDapagliflozin Propanediol117$101,596
XareltoRivaroxaban56$69,157
Repatha SureclickEvolocumab26$37,919
BrilintaTicagrelor30$29,851
Praluent PenAlirocumab22$20,137
DapagliflozinDapagliflozin Propanediol14$13,817
NexletolBempedoic Acid22$10,061
Nebivolol Hcl167$7,995
VascepaIcosapent Ethyl12$4,724
Metoprolol Succinate308$4,381
Rosuvastatin Calcium278$3,644
Icosapent Ethyl18$3,145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$317,588287 claims
NovartisEntresto$15,159$209,517224 claims
AstraZenecaFarxiga, Brilinta$146$131,448147 claims
Johnson & JohnsonXarelto$26$69,15756 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Watertown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →